Identification of Small Molecule Inhibitors of the Mitotic Kinase Haspin by High-Throughput Screening Using a Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer Assay

Abstract

Haspin/Gsg2 is a kinase that phosphorylates histone H3 at Thr-3 (H3T3ph) during mitosis. Its depletion by RNA interference results in failure of chromosome alignment and a block in mitosis. Haspin, therefore, is a novel target for development of antimitotic agents. We report the development of a high-throughput time-resolved fluorescence resonance energy transfer (TR-FRET) kinase assay for haspin. Histone H3 peptide was used as a substrate, and a europium-labeled H3T3ph phosphospecific monoclonal antibody was used to detect phosphorylation. A library of 137632 small molecules was screened at K_m concentrations of ATP and peptide to allow identification of diverse inhibitor types. Reconfirmation of hits and IC₅₀ determinations were carried out with the TR-FRET assay and by a radiometric assay using recombinant histone H3 as the substrate. A preliminary assessment of specificity was made by testing inhibition of 2 unrelated kinases. EC₅₀ values in cells were determined using a cell-based ELISA of H3T3ph. Five compounds were selected as leads based on potency and chemical structure considerations. These leads form the basis for the development of specific inhibitors of haspin that will have clear utility in basic research and possible use as starting points for development of antimitotic anticancer therapeutics. (Journal of Biomolecular Screening 2008:1025-1034)

Keywords

antimitotics chromatin haspin kinase time-resolved fluorescence resonance energy transfer

References

Jackson JR , Patrick DR , Dar MM , Huang PS : Targeted anti-mitotic therapies: can we improve on tubulin agents ? Nat Rev Cancer 2007;7:107-117.

Keen N. , Taylor S. : Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004;4:927-936.

Mountzios G. , Terpos E. , Dimopoulos MA : Aurora kinases as targets for cancer therapy . Cancer Treat Rev 2008 ;34:175-182.

Strebhardt K. , Ullrich A. : Targeting polo-like kinase 1 for cancer therapy . Nat Rev Cancer 2006;6:321-330.

Dai J. , Sultan S. , Taylor SS , Higgins JMG : The kinase haspin is required for mitotic histone H3 Thr 3 phosphorylation and normal metaphase chromosome alignment. Genes Dev 2005;19:472-488.

Dai J. , Higgins JMG : Haspin: a mitotic histone kinase required for metaphase chromosome alignment . Cell Cycle 2005;4:665-668.

Dai J. , Sullivan BA , Higgins JMG : Regulation of mitotic chromosome cohesion by Haspin and Aurora B. Dev Cell 2006;11:741-750.

de Cárcer G. , de Castro IP , Malumbres M. : Targeting cell cycle kinases for cancer therapy . Curr Med Chem 2007;14:969-985.

Schmidt M. , Bastians H. : Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drug Resist Updat 2007;10: 162-181.

10.

Higgins JMG : The Haspin gene: location in an intron of the Integrin αE gene, associated transcription of an Integrin αE-derived RNA and expression in diploid as well as haploid cells. Gene 2001;267:55-69.

11.

Higgins JMG : Haspin-like proteins: a new family of evolutionarily conserved putative eukaryotic protein kinases. Prot Sci 2001;10:1677-1684.

12.

Higgins JMG : Structure, function and evolution of haspin and haspin-related proteins, a distinctive group of eukaryotic protein kinases . Cell Mol Life Sci 2003;60:446-462.

13.

Kannan N. , Taylor SS , Zhai Y. , Venter JC , Manning G. : Structural and functional diversity of the microbial kinome. PLoS Biol 2007;5:e17.

14.

Taylor S. , Peters JM : Polo and Aurora kinases: lessons derived from chemical biology. Curr Opin Cell Biol 2008;20:77-84.

15.

Mathis G. : Probing molecular interactions with homogeneous techniques based on rare earth cryptates and fluorescence energy transfer. Clin Chem 1995;41:1391-1397.

16.

Hemmilä I. : LANCETM: Homogeneous assay platform for HTS. J Biomol Screen 1999;4:303-308.

17.

Mathis G. : HTRF® technology. J Biomol Screen 1999;4:309-314.

18.

Zhang JH , Chung TD , Oldenburg KR : A simple statistical parameter for use in evaluation and validation of high-throughput screening assays. J Biomol Screen 1999;4:67-73.

19.

Luger K. , Mader AW , Richmond RK , Sargent DF , Richmond TJ : Crystal structure of the nucleosome core particle at 2.8 Å resolution . Nature 1997;389:251-260.

20.

Case A. , Ni J. , Yeh LA , Stein RL : Development of a mechanism-based assay for tissue transglutaminase-results of a high-throughput screen and discovery of inhibitors. Anal Biochem 2005;338:237-244.